Literature DB >> 27679399

Influence of volumetric 4'-[methyl-11C]-thiothymidine PET/CT parameters for prediction of the clinical outcome of head and neck cancer patients.

Hiroshi Hoshikawa1, Terushige Mori2, Yukito Maeda3, Satoshi Takahashi2, Yohei Ouchi2, Yuka Yamamoto3, Yoshihiro Nishiyama3.   

Abstract

OBJECTIVE: This prospective study compared the value of pretreatment 4'-[methyl-11C]-thiothymidine (11C-4DST) volumetric parameters and those of 2-deoxy-2-[18F] fluoro-D-glucose (18F-FDG) in predicting the clinical outcome in patients with head and neck squamous cell carcinoma (HNSCC).
METHODS: Fifty patients with HNSCC underwent 11C-4DST PET/CT and 18F-FDG PET/CT prior to anticancer therapy. 18F-FDG metabolic tumor volume (18F-FDG MTV) and total lesion glycolysis (TLG) were calculated from 18F-FDG PET, and 11C-4DST MTV and total lesion proliferation (TLP) were calculated from 11C-4DST PET. All parameters were measured for the primary lesion and metastatic lymph nodes. Associations between clinical factors and PET/CT parameters and prognostic value were analyzed.
RESULTS: Receiver-operating characteristic analysis revealed that MTV, TLG, and TLP acquired from the primary lesion and metastatic lymph nodes were good parameters for predicting disease relapse and death. The area under the curves (AUCs) ranged from 0.63 to 0.71 for 18F-FDG PET/CT parameters. The AUCs of 11C-4DST PET/CT parameters were larger than those of 18F-FDG (range 0.72-0.81). Univariate analysis revealed that individuals with tumors showing a high value for any PET/CT parameter were at a significantly increased risk of relapse. Upon multivariate analysis, 18F-FDG MTV, 11C-4DST MTV and 11C-4DST TLP were significant independent factors for relapse-free survival (P = 0.04, P = 0.0001 and P = 0.0005, respectively).
CONCLUSION: Pretreatment 11C-4DST PET/CT volume-based parameters can provide important prognostic information about patients with HNSCC.

Entities:  

Keywords:  11C-4DST PET/CT; 18F-FDG PET/CT; Head and neck carcinoma; Metabolic tumor volume; Total lesion proliferation

Mesh:

Substances:

Year:  2016        PMID: 27679399     DOI: 10.1007/s12149-016-1131-6

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  5 in total

1.  Interim 4'-[methyl-11C]-thiothymidine PET for predicting the chemoradiotherapeutic response in head and neck squamous cell carcinoma: comparison with [18F]FDG PET.

Authors:  Katsuya Mitamura; Takashi Norikane; Yuka Yamamoto; Kengo Fujimoto; Yasukage Takami; Hiroshi Hoshikawa; Jun Toyohara; Yoshihiro Nishiyama
Journal:  EJNMMI Res       Date:  2021-02-10       Impact factor: 3.138

2.  Utility and limitations of metabolic parameters in head and neck cancer: finding a practical segmentation method.

Authors:  Jefferson Rijo-Cedeño; Jorge Mucientes; Ithzel María Villarreal; Ana Royuela; Patricia García Vicente; José Ramón García-Berrocal
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-05-02       Impact factor: 3.236

3.  Clinical value of PET/CT with carbon-11 4DST in the evaluation of malignant and benign lung tumors.

Authors:  Ryuichi Nishii; Tsuneo Saga; Hitomi Sudo; Takashi Togawa; Junpei Kuyama; Toshiaki Tani; Takamasa Maeda; Masato Kobayashi; Toshihiko Iizasa; Masato Shingyoji; Makiko Itami; Kazunori Kawamura; Hiroki Hashimoto; Kana Yamazaki; Kentaro Tamura; Tatsuya Higashi
Journal:  Ann Nucl Med       Date:  2021-01-02       Impact factor: 2.668

4.  Relationships between histogram analysis of ADC values and complex 18F-FDG-PET parameters in head and neck squamous cell carcinoma.

Authors:  Hans-Jonas Meyer; Sandra Purz; Osama Sabri; Alexey Surov
Journal:  PLoS One       Date:  2018-09-06       Impact factor: 3.240

5.  Efficacy of 4'-[methyl-11C] thiothymidine PET/CT before and after neoadjuvant therapy for predicting therapeutic responses in patients with esophageal cancer: a pilot study.

Authors:  Masatoshi Hotta; Ryogo Minamimoto; Kazuhiko Yamada; Kyoko Nohara; Daisuke Soma; Kazuhiko Nakajima; Jun Toyohara; Kei Takase
Journal:  EJNMMI Res       Date:  2019-01-30       Impact factor: 3.138

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.